10-K/A: Hologic Amends 10-K, Details Executive Pay & Merger Impact

Hologic, Inc. filed an amendment to its annual report, providing detailed executive compensation, corporate governance updates, and the impact of its recent merger on equity awards.

Summary

• The company filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended September 27, 2025, to include information required by Part III, which covers Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Accounting Fees.
• New certifications from the principal executive officer and principal financial officer were included with this amendment.
• The executive compensation program for fiscal 2025 emphasized pay-for-performance, with short-term incentives (STIP) based on adjusted revenue and adjusted EPS, and long-term incentives (LTIP) comprising Performance Stock Units (PSUs), Restricted Stock Units (RSUs), and stock options.
• For fiscal 2025, adjusted revenue reached $4.063 billion (51% of target $4.172 billion), and adjusted EPS was $4.33 (114% of target $4.30), resulting in an overall STIP payout of 76% of target.
• Long-term incentive PSUs for the FY2022-FY2024 performance period vested at 169% of target, and for the FY2023-FY2025 period, vested at 113% of target, reflecting strong performance in adjusted Free Cash Flow (FCF), Return on Invested Capital (ROIC), and relative Total Shareholder Return (TSR).
• In connection with the merger agreement dated October 21, 2025, certain executive officers received cash retention awards totaling $2.25 million, subject to clawback provisions.
• The ratio of CEO Stephen P. MacMillan's total compensation ($15,931,655) to the median employee's total compensation ($90,609) for fiscal 2025 was approximately 176 to 1.
• The Board of Directors saw new appointments and departures, including Martin Madaus joining in December 2024 and Wayde McMillan in April 2025, while Sally W. Crawford and Scott T. Garrett did not stand for re-election.

Sentiment

Score: 7

Explanation: The filing indicates solid performance in key long-term metrics and EPS, alongside a well-structured compensation program aligned with shareholder interests. While revenue slightly missed targets, the overall financial health and governance appear strong, and the merger details suggest strategic activity. The cash retention awards and equity treatment in the merger are positive for executives.

Positives

• Strong performance in long-term incentive metrics: FY2022 PSUs vested at 169% of target, and FY2023 PSUs vested at 113% of target, indicating effective long-term value creation.
• Adjusted EPS for fiscal 2025 exceeded its target at $4.33 (114% of target $4.30), demonstrating strong earnings performance.
• The company's say-on-pay vote approval increased from 69% in 2021 to 84% in 2025, indicating strong stockholder support for compensation practices and governance.
• Robust corporate governance practices are in place, including a golden parachute policy, compensation recoupment (clawback) policy, meaningful stock ownership guidelines, and an independent compensation consultant.
• The Audit and Finance Committee determined that the provision of services by Ernst & Young LLP was compatible with maintaining auditor independence, reflecting sound financial oversight.

Negatives

• Adjusted revenue for fiscal 2025 was below target at $4.063 billion (51% of target $4.172 billion), indicating a shortfall in top-line growth for the year.
• The overall Short-Term Incentive Plan (STIP) payout for fiscal 2025 was 76% of target, primarily due to the underperformance in adjusted revenue.
• Some stock options with an exercise price at or above $79.00 per share will be canceled for no additional consideration in connection with the merger, potentially impacting some option holders negatively.

Risks

• The company operates in a 'challenging macro-economic environment,' which can impact financial performance.
• Individual performance objectives for Named Executive Officers (NEOs) were aligned with 'top risks identified in our annual enterprise risk management process,' including challenges in driving global growth, strengthening the product pipeline, and succession planning and talent development.
• The Compensation Committee aims to balance focusing management on disciplined capital investment with not disincentivizing acquisitions, particularly of innovative companies, which could create a tension regarding Return on Invested Capital (ROIC) metrics.

Future Outlook

The company's compensation strategy is designed to promote sustainable long-term growth and stockholder value, with performance measures linked to strategic goals such as organic growth, efficient capital deployment, and business development. Future adjustments to executive salaries will align with market trends and organizational growth, incentivizing sustained performance and commitment. The company continues to focus on strengthening its product pipeline for 2027 and beyond through robust research and development investments and strategic acquisitions.

Management Comments

• "We believe that our compensation programs should motivate high performance among our NEOs within an entrepreneurial, incentive-driven culture and that compensation levels should reflect the achievement of shortand long-term performance objectives."
• "We aim to establish overall target compensation (compensation received when achieving expected results) that is competitive with that being offered to individuals holding comparable positions at other public companies with which we compete for business and talent."
• "We believe our stockholders continue to endorse our annual compensation program as it has evolved."
• "The Compensation Committee believes that increases in executive salaries from time to time are essential to stay competitive in the market, retain top talent, and recognize the growing responsibilities and contributions of our leaders."
• "The Compensation Committee continues to view the goals as challenging as it looks to create a balance between focusing management on a forward looking, disciplined approach to capital investment to optimize stockholder return, while also not disincentivizing management to pursue acquisitions, particularly of innovative companies that can materially drive longer-term future growth."

Industry Context

The company operates within the competitive med-tech and biopharmaceutical industries, as evidenced by the backgrounds of its board members and the peer groups used for compensation benchmarking. Its focus on organic growth, efficient capital use, and strategic acquisitions (like Gynesonics) reflects broader industry trends towards innovation and market consolidation. The company's compensation practices are benchmarked against a Primary Peer Group of comparable companies in terms of size and industry, as well as a Supplemental Practices Peer Group of larger companies, indicating a commitment to competitive talent attraction and retention within these sectors.

Comparison to Industry Standards

• The company's executive compensation program is benchmarked against a Primary Peer Group including Agilent Technologies, IDEXX Laboratories, Steris Plc, Baxter International Inc., Illumina, Inc., Teleflex Incorporated, Boston Scientific Corporation, Intuitive Surgical, Inc., The Cooper Companies, Inc., DENTSPLY Sirona, Inc., ResMed, Inc., Waters Corporation, Edwards Lifesciences Corp., Revvity, Inc., and Zimmer Biomet Holdings, Inc.
• A Supplemental Practices Peer Group of larger companies, including Abbott Laboratories, Johnson & Johnson, Stryker Corporation, Becton, Dickinson and Company, Medtronic plc, and Thermo Fisher Scientific Inc., is referenced for compensation design characteristics.
• The TSR Peer Group, used for relative TSR performance, includes companies from both the Primary Peer Group and the internal investor relations comparator group, such as Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Bruker Corporation, DENTSPLY Sirona, Inc., DexCom, Inc., Edwards Lifesciences Corp., IDEXX Laboratories, Inc., Illumina, Inc., Integra LifeSciences Holdings Corp, Intuitive Surgical, Inc., Laboratory Corp. of America Holdings, Mettler-Toledo International Inc., Qiagen NV, Quest Diagnostics Inc., ResMed Inc., Revvity, Inc., STERIS plc, Stryker Corporation, The Cooper Companies, Inc., Thermo Fisher Scientific Inc., Waters Corporation, and Zimmer Biomet Holdings, Inc.
• The company's adjusted ROIC goals (threshold 10%, target 13%, maximum 16%) are maintained to balance disciplined capital investment with the pursuit of acquisitions, aiming to optimize stockholder return while acknowledging the potential impact of innovative company acquisitions on ROIC.
• The TSR PSUs require achievement of relative TSR at the 95th percentile for maximum payout, which the company considers a more challenging threshold compared to the 75th percentile often used by other companies.

Management Changes

Corporate Governance

Related Party Transactions

• The Audit and Finance Committee reviewed and approved one related-party transaction for fiscal 2025 involving Peter Wells, the stepson of former director Sally Crawford.
• Mr. Wells is employed as a Manager, Solution Delivery Lead, and earned approximately $193,000 in total annual compensation during fiscal 2025, commensurate with his peers and standard company practices.

Stakeholder Impact

• Shareholders: The merger agreement and its impact on equity awards, along with the detailed executive compensation and governance practices, directly affect shareholder value and confidence. The increase in say-on-pay approval indicates positive shareholder sentiment regarding compensation.
• Employees: The compensation structure, including base salaries, short-term and long-term incentives, and retirement benefits, directly impacts employee motivation, retention, and overall well-being. The CEO to median employee pay ratio provides transparency on internal compensation equity.
• Executive Officers: The detailed compensation plans, cash retention awards, and treatment of equity in the merger significantly impact the financial incentives and wealth of the named executive officers.
• Customers/Suppliers: The company's focus on driving global growth, strengthening the product pipeline, and ensuring quality products (as mentioned in executive performance goals) indirectly benefits customers and suppliers through improved offerings and operational excellence.

Next Steps

• Closing of the merger with Hopper Parent Inc. and Hopper Merger Sub Inc.
• Payment of unvested Deferred Compensation Plan (DCP) amounts within 45 days following the closing of the merger.
• Execution of product launch plans for 2025 and 2026, and continued pursuit of strategic acquisitions or external technologies to drive longer-term growth.
• Readiness for the launch of GI Bacterial panels in 2026.
• Continued focus on succession planning and talent development across the organization.

Key Dates

Recommendation

The filing provides detailed compensation and governance information, but no new financial results beyond what was likely in the original 10-K. The strong performance in long-term incentive metrics and exceeding EPS targets are positive, indicating effective management and value creation. However, the slight miss on adjusted revenue for the STIP suggests some operational challenges. The ongoing merger introduces a significant event, and while the details on equity treatment are provided, the overall impact on future share price will depend on the merger's terms and market reception, which are not fully detailed here. Given the mixed short-term financial performance but strong long-term incentive achievements and the pending merger, a 'hold' recommendation is appropriate, awaiting further clarity on the merger's completion and its strategic implications.

Keywords

Hologic, SEC Filing, 10-K/A, Executive Compensation, Corporate Governance, Merger, Equity Awards, Financial Performance, Adjusted Revenue, Adjusted EPS, Free Cash Flow, ROIC, TSR, Medical Devices, Biopharmaceutical, Diagnostics